Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$39.53−0.46 (-1.15%)
Close on Nov 13, 2026Market cap $28.55BP/E –Yield –
Roivant Sciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Roivant Sciences's enterprise value was $27.09B on Nov 11, 2026, against $10.41B a year earlier. Over the last 5 years it ranged from $705.89M to $27.09B, with a median of $4.36B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $27.09B | +145.8% |
| 2025 | Dec 31, 2025 | $11.02B | +196.7% |
| 2024 | Dec 31, 2024 | $3.72B | -53.6% |
| 2023 | Dec 29, 2023 | $8.01B | +81.9% |
| 2022 | Dec 30, 2022 | $4.40B | -11.6% |
| 2021 | Dec 31, 2021 | $4.98B | – |
See a number that looks wrong?